Jeffrey Stein

Jeffrey Stein's Title

Jeffrey Stein is the President and Chief Executive Officer, a role in which he oversees the strategic direction and operational activities of his current organization. His leadership is characterized by a strong background in biotechnology and pharmaceuticals, particularly in the development of innovative therapies. Stein's extensive experience in executive roles underscores his capability to drive growth and innovation in complex, competitive markets.

Jeffrey Stein's Company

Jeffrey Stein has led several high-profile biotechnology firms. Notably, he served as the CEO of Trius Therapeutics, where he spearheaded the successful development of the antibacterial drug tedizolid, which has had significant clinical impact. His leadership at Trius Therapeutics exemplifies his ability to guide companies through critical stages of drug development and regulatory approval, leading to successful market entries.

Jeffrey Stein's Education and Expertise

Jeffrey Stein boasts a robust academic background, having conducted postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology. He also completed his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego. These prestigious fellowships highlight his deep expertise in scientific research and his commitment to advancing knowledge in the field of biotechnology.

Jeffrey Stein's Background

Jeffrey Stein's professional journey is marked by significant achievements and roles in the biotechnology industry. He co-founded Quorex Pharmaceuticals and served as its Chief Scientific Officer until the company was acquired by Pfizer in 2005. Additionally, he has served as a Venture Partner and Kauffman Fellow with Sofinnova Ventures, where he leveraged his scientific acumen to guide investment decisions and support biotech startups. His broad experience in both scientific and executive roles provides him with a unique perspective on the biotech industry.

Jeffrey Stein's Achievements

Among Jeffrey Stein's notable achievements is his role in the development of tedizolid, an important antibacterial drug, during his tenure as CEO of Trius Therapeutics. He is also a founding Chairman and President of the Antimicrobials Working Group, an influential organization in the field. Furthermore, Stein serves as a Director of Ideaya Biosciences, where he chairs the compensation committee, contributing to the company's strategic governance. His accomplishments reflect a career dedicated to advancing medical science and fostering innovation in the pharmaceutical industry.